Exonate

Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.

2012

YEAR FOUNDED

2014

DATE FIRST INVESTED

Drug discovery – wet AMD and cancer
School of Medicine

Profile

Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.

Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.

@ExonateUK on Twitter